
    
      A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled,
      Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients with
      Parkinson's Disease
    
  